Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT04110327
Active, not recruiting Observational

An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease

NCT04110327 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Micro Medical Solution, Inc
Phase
Observational
Started
2019-10-31
Last updated
2026-06-29

Condition(s) studied

Peripheral Arterial DiseaseCritical Lower Limb Ischemia

Investigational drug(s) / intervention(s)

MicroStent

MicroStent: Treatment of arterial stenosis or occlusion with the MicroStent Peripheral Vascular Stent System

Study summary

Non-randomized, multicenter, combined prospective and retrospective cohort analysis consisting of a single arm treated with the MicroStent™ System.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Any subject with below the knee, at the ankle level or below the ankle peripheral arterial lesions previously treated or intended to be treated with the MicroStent® System per the current indications for use 2. For across the ankle joint intervention, distal runoff to digital branches or arcuate arteries must be present on angiography prior to MicroStent deployment 3. Subject's age is ≥ 18 years. 4. Subject must be willing to sign a patient informed consent form. Exclusion Criteria: 1. Subject is pregnant or planning to become pregnant during the study duration 2. Subject has a life expectancy of less than one (1) year 3. Subject has a known allergy to concomitant medication, contrast agents (that cannot be medically managed), anti-platelet, anti-coagulant or thrombolytic medications 4. Subject is enrolled in another study that has not reached its primary endpoint at the time of enrollment.

Primary outcome measure(s)

Trial sites (10)

FacilityCityRegionStatus
Univ.-Klinikum LKH Graz Graz Austria
OLV Hospital Aalst Belgium
A.Z. Sint-Blasius Dendermonde Belgium
ZOL Genk Genk Belgium
Klinikum Hochsauerland - Karolinen Hospital Arnsberg Germany
University Heart Center Freiburg - Bad Krozingen Bad Krozingen Germany
University of Leipzig Leipzig Germany
Policlinico Abano Terme Abano Terme Italy
Maria Cecilia Hospital Cotignola Italy
St. Antonius Ziekenhuis Nieuwegein Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04110327 on ClinicalTrials.gov ↗ ← All trials in the Netherlands